In summary, our findings demonstrate that SGLT-2 inhibitors improve blood pressure control and reduce cardiovascular morbidity in hypertensive patients, with or without diabetes, although patients with diabetes continue to experience higher absolute event rates. The gene discussed is SLC5A2; the disease is diabetes mellitus.